CY1114311T1 - Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης - Google Patents

Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης

Info

Publication number
CY1114311T1
CY1114311T1 CY20131100341T CY131100341T CY1114311T1 CY 1114311 T1 CY1114311 T1 CY 1114311T1 CY 20131100341 T CY20131100341 T CY 20131100341T CY 131100341 T CY131100341 T CY 131100341T CY 1114311 T1 CY1114311 T1 CY 1114311T1
Authority
CY
Cyprus
Prior art keywords
immediate release
oral absorption
butyloxyminomethyl
trit
therapeutic systems
Prior art date
Application number
CY20131100341T
Other languages
Greek (el)
English (en)
Inventor
Antonio Longo
Silvia Pace
Massimo Pedrani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1114311T1 publication Critical patent/CY1114311T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20131100341T 2005-08-04 2013-04-25 Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης CY1114311T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000418A ITRM20050418A1 (it) 2005-08-04 2005-08-04 Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
EP06777710.2A EP1915153B1 (en) 2005-08-04 2006-07-11 Immediate release therapeutic systems for improved oral absorption of 7-[(e)-tert-butyloxyiminomethyl]camtothecin

Publications (1)

Publication Number Publication Date
CY1114311T1 true CY1114311T1 (el) 2016-08-31

Family

ID=37727667

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100341T CY1114311T1 (el) 2005-08-04 2013-04-25 Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης

Country Status (19)

Country Link
US (1) US20090053307A1 (cg-RX-API-DMAC7.html)
EP (1) EP1915153B1 (cg-RX-API-DMAC7.html)
JP (1) JP5225084B2 (cg-RX-API-DMAC7.html)
KR (1) KR101301548B1 (cg-RX-API-DMAC7.html)
CN (1) CN101287466B (cg-RX-API-DMAC7.html)
AU (1) AU2006278114B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0614471A2 (cg-RX-API-DMAC7.html)
CA (1) CA2612080C (cg-RX-API-DMAC7.html)
CY (1) CY1114311T1 (cg-RX-API-DMAC7.html)
DK (1) DK1915153T3 (cg-RX-API-DMAC7.html)
ES (1) ES2407408T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130364T1 (cg-RX-API-DMAC7.html)
IT (1) ITRM20050418A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008001029A (cg-RX-API-DMAC7.html)
PL (1) PL1915153T3 (cg-RX-API-DMAC7.html)
PT (1) PT1915153E (cg-RX-API-DMAC7.html)
RS (1) RS52777B (cg-RX-API-DMAC7.html)
SI (1) SI1915153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007017331A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
USD618617S1 (en) 2008-12-30 2010-06-29 Multiway Industries (Hk) Ltd. Three way electrical plug
US7892036B2 (en) * 2008-12-30 2011-02-22 Multiway Industries (Hk) Ltd. Electrical wall tap assembly
USD618175S1 (en) 2009-10-15 2010-06-22 Multiway Industries (Hk) Ltd. Three-outlet surge-protected adaptor
USD616823S1 (en) 2009-10-15 2010-06-01 Multiway Industries (Hk) Ltd. Single-outlet surge-protected adaptor
WO2011071194A1 (ko) * 2009-12-08 2011-06-16 주식회사 일화 20-O-β-D-글루코피라노실-20(S)-프로토파낙사디올을 포함하는 고체분산체
USD651977S1 (en) 2011-01-10 2012-01-10 Multiway Industries (Hk) Ltd. Multiple outlet electrical connector
CN108066311B (zh) * 2017-12-26 2020-09-08 兆科(广州)肿瘤药物有限公司 一种吉马替康胶囊及其制备方法
USD958079S1 (en) 2019-08-30 2022-07-19 Multiway Industries (Hk) Ltd. 3-way electrical tap
USD955993S1 (en) 2019-08-30 2022-06-28 Multiway Industries (Hk) Ltd. 3-way electrical tap
CN111529497A (zh) * 2020-02-11 2020-08-14 兆科(广州)肿瘤药物有限公司 一种吉马替康药物固体分散组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
KR20070058028A (ko) * 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
WO2005092302A2 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
ES2395930T3 (es) * 2004-12-21 2013-02-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Procedimiento estereoselectivo y formas cristalinas de una camptotecina

Also Published As

Publication number Publication date
KR20080031945A (ko) 2008-04-11
CN101287466B (zh) 2014-11-05
PT1915153E (pt) 2013-06-05
WO2007017331A2 (en) 2007-02-15
HRP20130364T1 (hr) 2013-05-31
AU2006278114A1 (en) 2007-02-15
SI1915153T1 (sl) 2013-06-28
AU2006278114B2 (en) 2011-06-23
BRPI0614471A2 (pt) 2011-03-29
MX2008001029A (es) 2008-03-14
HK1125293A1 (en) 2009-08-07
EP1915153B1 (en) 2013-04-10
ES2407408T3 (es) 2013-06-12
PL1915153T3 (pl) 2013-09-30
RS52777B (sr) 2013-10-31
JP2009503013A (ja) 2009-01-29
EP1915153A2 (en) 2008-04-30
CA2612080C (en) 2013-09-03
WO2007017331A3 (en) 2007-09-27
CN101287466A (zh) 2008-10-15
KR101301548B1 (ko) 2013-09-06
ITRM20050418A1 (it) 2007-02-05
JP5225084B2 (ja) 2013-07-03
CA2612080A1 (en) 2007-02-15
US20090053307A1 (en) 2009-02-26
DK1915153T3 (da) 2013-06-24

Similar Documents

Publication Publication Date Title
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CR8766A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
CY1118219T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1109265T1 (el) Συνθεσεις που συμπεριλαμβανουν δροσπιρενονη μοριακα διασπαρμενη
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DE602005027707D1 (de) Isoindolin-verbindungen und deren verwendungen
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1115709T1 (el) Φαρμακευτικη μορφη περιεχουσα φλουπιρτινη με ελεγχομενη αποδεσμευση της δραστικης ουσιας